{
  "docId": "019dd923-5ca1-7489-b634-d3738a63434c",
  "docSlug": "2862941a98bffda6",
  "documentTitle": "Corporate Ventures in Sweden",
  "authorId": "BCG",
  "authorName": "BCG",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.445,
  "pageNumber": 25,
  "pageCount": 28,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "market_landscape",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The chart is a 2x2-style matrix mapping operational capability vs time to impact.",
  "elementsJson": [
    "bullet_list",
    "quadrant_chart",
    "logo_grid"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b634-d3738a63434c/25",
  "deckHref": "/decks/019dd923-5ca1-7489-b634-d3738a63434c",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b634-d3738a63434c.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b634-d3738a63434c#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.55,
        "y": 0.28
      },
      "kind": "chart",
      "text": "Matrix of Link to operational capability vs Time to impact for BU",
      "attrs": null,
      "subkind": "box",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb300b4a-385d-42b3-b7e5-1d582e2d0b06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "framework",
      "text": "2x2 Matrix",
      "attrs": null,
      "subkind": null,
      "toolName": "Structuring frame",
      "toolSlug": "structuring-frame",
      "confidence": null,
      "componentId": "019dd951-acb6-775d-928b-2b6e5a71e09c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.15,
        "y": 0.6
      },
      "kind": "list",
      "text": "BioVenture Hub: Incubation hub for start-ups and academic groups providing know-how, labs and offices; Objective to expose AstraZeneca to innovation with lower investment risk; Target companies are about to enter clinical phase and should be a suitable collaboration partner",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35026a5c-ae94-4c9a-83a6-d93c1d365741",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.15,
        "y": 0.3
      },
      "kind": "list",
      "text": "Medimmune Ventures: Invests in small and large molecules, vaccines, pharmaceutical technologies and platforms; Invests in early-to late-stage products and technologies; IT companies pertaining to discovery, development and commercialization of pharmaceutical products are also of interest",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90d896f5-9dd7-4bdf-8498-cde80d90808a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: AstraZeneca; Medimmune Ventures; BCG analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3942c05-4e2a-492a-bfd0-05d1dca477f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "AstraZeneca ext. innovation includes venturing & incubation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "745db9c9-da32-4196-9811-d2a347c8ad7e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "4a4f9013-4c08-49a4-9148-615c1f871267",
      "evidence": "chart/box: Matrix of Link to operational capability vs Time to impact for BU",
      "confidence": 0.9
    },
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "019dd95a-12a6-770e-916e-923df07b8e7e",
      "evidence": "Title 'AstraZeneca ext. innovation includes venturing & incubation'.",
      "confidence": 85
    },
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "019dd95a-12a6-770e-916e-999663b476f5",
      "evidence": "2x2 grid with labelled axes (operational capability × time).",
      "confidence": 75
    },
    {
      "name": "Contrast Principle",
      "slug": "contrast-principle",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "019dd95a-1321-706c-9a5a-cf0c471557eb",
      "evidence": "Two CV vehicles plotted as overlapping rectangles for comparison.",
      "confidence": 65
    },
    {
      "name": "Metaphor & Analogy",
      "slug": "metaphor-analogy",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "019dd95a-12a6-770e-916e-947ff20e393c",
      "evidence": "Same 2x2 matrix template plots Medimmune Ventures vs BioVenture Hub.",
      "confidence": 65
    }
  ],
  "frameworks": [
    {
      "name": "2x2 Matrix",
      "slug": null,
      "matchId": "019dd95a-1ca6-71be-9e57-45f481760564",
      "evidence": "Inventory hint confirmed: axes 'Close-to-core/Adjacent/Completely new' × '1-3/4-6/7-10 years'.",
      "confidence": 85
    },
    {
      "name": "matrix-2x2",
      "slug": null,
      "matchId": "9c23f513-d87b-4f72-8436-08052f37bdc0",
      "evidence": "The chart maps two variables (operational capability and time to impact) to position two business units.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 26,
      "from": 21,
      "name": "Zoom In",
      "slug": "06-zoom-in",
      "bestFor": "Technical deep-dives, case studies, detailed analysis",
      "matchId": "019dd95a-088b-72c8-b7e2-e50f73c26705",
      "evidence": "Each case (MTGx, Volvo VC, AstraZeneca) gets a detail slide + press-clipping page.",
      "position": 6,
      "objective": "Deep-dive on each Swedish CV case in the appendix",
      "structure": "The Big Picture -> Key Area of Focus -> Specific Detail -> Implication",
      "confidence": 75,
      "description": "Start broad, then progressively focus on specific details that prove your point"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}